Form D · Biotechnology
Theravie Pharma, Inc.
San Diego, CA · CIK 0002160768
Offering snapshot reported Oct 19, 2026 · SEC filing
- Reported sold
- $750K Offering amount: $2.25M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 29, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 19, 2026 | Initial | $750,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-601656
Simple Agreement for Future Equity (SAFE), a contractual right to receive equity securities upon the occurrence of specified future financing events.
Source: Form D, filed Oct 19, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Samia Lina Helena Almoughrabie | Director, Executive |
| Richard Louis Gallo | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
8525 Gibbs Drive Suite 304
San Diego, CA, 92123
Phone: 858-308-2977
San Diego, CA, 92123
Phone: 858-308-2977